Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose

Description

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC.

Conditions

Autism Spectrum Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC.

Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: a Single-dose Challenge Study

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose

Condition
Autism Spectrum Disorder
Intervention / Treatment

-

Contacts and Locations

Stanford

Stanford University School of Medicine, Stanford, California, United States, 94305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * children between 3 years and 12 years 11 months at the time of consent
  • * diagnosis of Autism Spectrum Disorder confirmed with the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule-2 (ADOS-2), or Brief Observation of Symptoms of Autism (BOSA), or Childhood Autism Rating Scale- Second Edition (CARS-2).
  • * at least moderate Restricted and Repetitive Behaviors severity defined by a Children's Yale-Brown Obsessive Compulsive Scale for children with autism spectrum disorder score ≥ 11,
  • * physical development indicative of prepubescence as defined by the criteria for Tanner Stage 1,
  • * medically stable,
  • * passes MR safety screening (e.g., no metal in the body).
  • * presence of known genetic abnormalities associated with Autism Spectrum Disorder (e.g. Fragile X),
  • * current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia),
  • * presence of significant medical problems that would interfere with participation,
  • * the inability of at least one caregiver to speak/read English to a sufficient level to complete study requirements and materials,
  • * individuals taking antioxidant agents and glutathione prodrugs, or
  • * the inability/unwillingness to swallow an agent during the screening visit.

Ages Eligible for Study

3 Years to 12 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

John Hegarty, PhD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2027-01